Report Detail

Pharma & Healthcare Global Peptide Antibiotics Market Insights, Forecast to 2025

  • RnM3356602
  • |
  • 25 April, 2019
  • |
  • Global
  • |
  • 117 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The global Peptide Antibiotics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Peptide Antibiotics market based on company, product type, end user and key regions.

This report studies the global market size of Peptide Antibiotics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Peptide Antibiotics in these regions.
This research report categorizes the global Peptide Antibiotics market by top players/brands, region, type and end user. This report also studies the global Peptide Antibiotics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Novartis
GlaxoSmithKline
Eli Lilly
Theravance
Vicuron Pharmaceuticals
Savara Pharmaceuticals
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Phosphagenics
Pacgen Life Science Corporation

Market size by Product
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Market size by End User
Pharma & Healthcare
Food Industry
Commodities
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Peptide Antibiotics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Peptide Antibiotics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Peptide Antibiotics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Peptide Antibiotics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Peptide Antibiotics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Peptide Antibiotics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Peptide Antibiotics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Peptide Antibiotics Market Size Growth Rate by Product
      • 1.4.2 Ribosomal Synthesized Peptide Antibiotics
      • 1.4.3 Non-Ribosomally Synthesized Peptide Antibiotics
    • 1.5 Market by End User
      • 1.5.1 Global Peptide Antibiotics Market Size Growth Rate by End User
      • 1.5.2 Pharma & Healthcare
      • 1.5.3 Food Industry
      • 1.5.4 Commodities
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Peptide Antibiotics Market Size
      • 2.1.1 Global Peptide Antibiotics Revenue 2014-2025
      • 2.1.2 Global Peptide Antibiotics Sales 2014-2025
    • 2.2 Peptide Antibiotics Growth Rate by Regions
      • 2.2.1 Global Peptide Antibiotics Sales by Regions
      • 2.2.2 Global Peptide Antibiotics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Peptide Antibiotics Sales by Manufacturers
      • 3.1.1 Peptide Antibiotics Sales by Manufacturers
      • 3.1.2 Peptide Antibiotics Sales Market Share by Manufacturers
      • 3.1.3 Global Peptide Antibiotics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Peptide Antibiotics Revenue by Manufacturers
      • 3.2.1 Peptide Antibiotics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Peptide Antibiotics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Peptide Antibiotics Price by Manufacturers
    • 3.4 Peptide Antibiotics Manufacturing Base Distribution, Product Types
      • 3.4.1 Peptide Antibiotics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Peptide Antibiotics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Peptide Antibiotics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Peptide Antibiotics Sales by Product
    • 4.2 Global Peptide Antibiotics Revenue by Product
    • 4.3 Peptide Antibiotics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Peptide Antibiotics Breakdown Data by End User

    6 North America

    • 6.1 North America Peptide Antibiotics by Countries
      • 6.1.1 North America Peptide Antibiotics Sales by Countries
      • 6.1.2 North America Peptide Antibiotics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Peptide Antibiotics by Product
    • 6.3 North America Peptide Antibiotics by End User

    7 Europe

    • 7.1 Europe Peptide Antibiotics by Countries
      • 7.1.1 Europe Peptide Antibiotics Sales by Countries
      • 7.1.2 Europe Peptide Antibiotics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Peptide Antibiotics by Product
    • 7.3 Europe Peptide Antibiotics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Peptide Antibiotics by Countries
      • 8.1.1 Asia Pacific Peptide Antibiotics Sales by Countries
      • 8.1.2 Asia Pacific Peptide Antibiotics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Peptide Antibiotics by Product
    • 8.3 Asia Pacific Peptide Antibiotics by End User

    9 Central & South America

    • 9.1 Central & South America Peptide Antibiotics by Countries
      • 9.1.1 Central & South America Peptide Antibiotics Sales by Countries
      • 9.1.2 Central & South America Peptide Antibiotics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Peptide Antibiotics by Product
    • 9.3 Central & South America Peptide Antibiotics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Peptide Antibiotics by Countries
      • 10.1.1 Middle East and Africa Peptide Antibiotics Sales by Countries
      • 10.1.2 Middle East and Africa Peptide Antibiotics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Peptide Antibiotics by Product
    • 10.3 Middle East and Africa Peptide Antibiotics by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Peptide Antibiotics Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Novartis
      • 11.2.1 Novartis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis Peptide Antibiotics Products Offered
      • 11.2.5 Novartis Recent Development
    • 11.3 GlaxoSmithKline
      • 11.3.1 GlaxoSmithKline Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 GlaxoSmithKline Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 GlaxoSmithKline Peptide Antibiotics Products Offered
      • 11.3.5 GlaxoSmithKline Recent Development
    • 11.4 Eli Lilly
      • 11.4.1 Eli Lilly Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Eli Lilly Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Eli Lilly Peptide Antibiotics Products Offered
      • 11.4.5 Eli Lilly Recent Development
    • 11.5 Theravance
      • 11.5.1 Theravance Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Theravance Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Theravance Peptide Antibiotics Products Offered
      • 11.5.5 Theravance Recent Development
    • 11.6 Vicuron Pharmaceuticals
      • 11.6.1 Vicuron Pharmaceuticals Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Vicuron Pharmaceuticals Peptide Antibiotics Products Offered
      • 11.6.5 Vicuron Pharmaceuticals Recent Development
    • 11.7 Savara Pharmaceuticals
      • 11.7.1 Savara Pharmaceuticals Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Savara Pharmaceuticals Peptide Antibiotics Products Offered
      • 11.7.5 Savara Pharmaceuticals Recent Development
    • 11.8 AMP Therapeutics
      • 11.8.1 AMP Therapeutics Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 AMP Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 AMP Therapeutics Peptide Antibiotics Products Offered
      • 11.8.5 AMP Therapeutics Recent Development
    • 11.9 Hospira
      • 11.9.1 Hospira Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Hospira Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Hospira Peptide Antibiotics Products Offered
      • 11.9.5 Hospira Recent Development
    • 11.10 Kasten
      • 11.10.1 Kasten Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Kasten Peptide Antibiotics Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Kasten Peptide Antibiotics Products Offered
      • 11.10.5 Kasten Recent Development
    • 11.11 Madam Therapeutics
    • 11.12 Phosphagenics
    • 11.13 Pacgen Life Science Corporation

    12 Future Forecast

    • 12.1 Peptide Antibiotics Market Forecast by Regions
      • 12.1.1 Global Peptide Antibiotics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Peptide Antibiotics Revenue Forecast by Regions 2019-2025
    • 12.2 Peptide Antibiotics Market Forecast by Product
      • 12.2.1 Global Peptide Antibiotics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Peptide Antibiotics Revenue Forecast by Product 2019-2025
    • 12.3 Peptide Antibiotics Market Forecast by End User
    • 12.4 North America Peptide Antibiotics Forecast
    • 12.5 Europe Peptide Antibiotics Forecast
    • 12.6 Asia Pacific Peptide Antibiotics Forecast
    • 12.7 Central & South America Peptide Antibiotics Forecast
    • 12.8 Middle East and Africa Peptide Antibiotics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Peptide Antibiotics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Peptide Antibiotics . Industry analysis & Market Report on Peptide Antibiotics is a syndicated market report, published as Global Peptide Antibiotics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Peptide Antibiotics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,014.70
      4,522.05
      6,029.40
      3,595.80
      5,393.70
      7,191.60
      595,764.00
      893,646.00
      1,191,528.00
      328,029.00
      492,043.50
      656,058.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report